Carisma Therapeutics Inc. CARM shares are trading higher on Friday following the company’s announcement of a significant development in its collaboration with Moderna.
What To Know: Carisma has nominated its first in vivo CAR-M development candidate targeting Glypican-3 (GPC3) for the treatment of solid tumors, including hepatocellular carcinoma (HCC). This milestone has triggered a $2 million payment to Carisma from Moderna.
The development candidate leverages Carisma’s expertise in engineering chimeric antigen receptor monocytes and macrophages (CAR-M) with Moderna’s mRNA and lipid nanoparticle platform. This collaboration aims to create novel in vivo cell therapies for oncology, with pre-clinical data showing promising results in redirecting myeloid cells to attack cancer cells directly in vivo.
What Else: Michael Klichinsky, Co-Founder and Chief Scientific Officer at Carisma, emphasized the significance of targeting GPC3, a highly expressed tumor antigen in HCC. Lin Guey, Chief Scientific Officer of Therapeutics Research Ventures at Moderna, expressed excitement about the progress and the potential for further development of CAR-M therapies for solid tumors.
Additionally, HC Wainwright & Co. also reiterated a Buy rating on the stock, maintaining a price target of $8.
CARM Price Action: Carisma shares were up by 14.9% at $1.55 according to Benzinga Pro.
See Also: Germany Leads The Global Medical Cannabis Explosion
Image: Steve Buissine from Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
